Bharat Immunologicals & Biologicals Past Earnings Performance
Past criteria checks 0/6
Bharat Immunologicals & Biologicals's earnings have been declining at an average annual rate of -96.6%, while the Biotechs industry saw earnings growing at 3.3% annually. Revenues have been declining at an average rate of 90% per year.
Key information
-96.6%
Earnings growth rate
-97.2%
EPS growth rate
| Biotechs Industry Growth | 5.1% |
| Revenue growth rate | -90.0% |
| Return on equity | -23.5% |
| Net Margin | -241.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bharat Immunologicals & Biologicals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 77 | -185 | 153 | 0 |
| 30 Jun 23 | 341 | -166 | 153 | 0 |
| 31 Mar 23 | 446 | -166 | 152 | 0 |
| 31 Dec 22 | 590 | -138 | 168 | 0 |
| 30 Sep 22 | 764 | -94 | 159 | 0 |
| 30 Jun 22 | 747 | -157 | 150 | 0 |
| 31 Mar 22 | 784 | -88 | 139 | 0 |
| 31 Dec 21 | 720 | -193 | 158 | 0 |
| 30 Sep 21 | 797 | -159 | 166 | 0 |
| 30 Jun 21 | 804 | -104 | 170 | 0 |
| 31 Mar 21 | 853 | -181 | 145 | 0 |
| 31 Dec 20 | 930 | -28 | 113 | 0 |
| 30 Sep 20 | 962 | -57 | 113 | 0 |
| 30 Jun 20 | 790 | -75 | 104 | 0 |
| 31 Mar 20 | 668 | -102 | 114 | 0 |
| 31 Dec 19 | 1,142 | -160 | 107 | 0 |
| 30 Sep 19 | 940 | -141 | 104 | 0 |
| 30 Jun 19 | 906 | -82 | 97 | 0 |
| 31 Mar 19 | 836 | -58 | 98 | 0 |
| 31 Dec 18 | 347 | -43 | 104 | 0 |
| 30 Sep 18 | 309 | -36 | 103 | 0 |
| 30 Jun 18 | 315 | -38 | 103 | 0 |
| 31 Mar 18 | 348 | -43 | 103 | 0 |
| 31 Dec 17 | 745 | 3 | 119 | 0 |
| 30 Sep 17 | 940 | 12 | 123 | 0 |
| 30 Jun 17 | 997 | 52 | 123 | 0 |
| 31 Mar 17 | 1,242 | 65 | 102 | 0 |
| 31 Dec 16 | 1,218 | 27 | 151 | 0 |
| 30 Sep 16 | 1,368 | 6 | 150 | 0 |
| 30 Jun 16 | 1,392 | -34 | 151 | 0 |
| 31 Mar 16 | 1,280 | -62 | 128 | 0 |
| 31 Dec 15 | 926 | -93 | 125 | 0 |
| 30 Sep 15 | 1,174 | -44 | 123 | 0 |
| 30 Jun 15 | 1,288 | -20 | 93 | 0 |
| 31 Mar 15 | 1,462 | 15 | 163 | 0 |
| 31 Dec 14 | 2,264 | 90 | 173 | 0 |
| 30 Sep 14 | 2,211 | 113 | 182 | 0 |
| 30 Jun 14 | 2,213 | 116 | 121 | 0 |
| 31 Mar 14 | 2,028 | 64 | 171 | 0 |
| 31 Dec 13 | 1,692 | 56 | 121 | 0 |
Quality Earnings: 524663 is currently unprofitable.
Growing Profit Margin: 524663 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 524663's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 524663's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 524663 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.3%).
Return on Equity
High ROE: 524663 has a negative Return on Equity (-23.48%), as it is currently unprofitable.